

Revolutionizing Perioperative Care.

Senzime develops precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety.

Our portfolio, powered by proprietary smart algorithms, generates enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Q1 2024 summary.



Senzime Q1 2024: Record sales, once again

“Another quarter with record sales. We won our largest hospital deal to date, and we stabilized our expenses.

The market outlook remains strong, catalyzed by the recently published clinical guidelines.”

12,1

Million SEK in sales.


66%

Total sales growth vs. Q1 2023.

79%


US market sales growth vs. Q1 2023.

Q1 revenues (kSEK)




Senzime Q1 2024: Rolling 12-month sales continues to grow

Net sales rolling-12 months (kSEK)




Sales of TetraSens, rolling-12 months (kSEK)




Installed base of monitors grows, drives sales of disposable sensors

Total delivered base of TetraGraph-systems¹




Shipped TetraSens disposable sensors (accumulated units)



Note: 1) Includes monitors sold through direct and distributor sales, Fukuda and monitors placed at customer sites;
Source: Company information.

TetraGraph customer (hospital) growth

Number of active hospital accounts, end of period*



* Excludes accounts in smaller distribution markets.




33
New hospitals
in Q1 2024

>330
hospitals
in total



Utilization rate driven by leading hospital accounts

Utilization rate (linear trend), TetraSens use per week





March 2024:

**Senzime wins its
largest US deal to date
from leading Houston
based university
hospital system**

**“More than 250
TetraGraph
systems rolled
out during
2024”**

TetraGraph® technology inside and TetraSens on patient

手術室・ICUモニタリングの 安全性向上の為に

筋弛緩モニタリングの様々な測定方法が確立されている中で、本装置は筋活動電位により筋弛緩状態をモニタリングしています。

本装置は、患者の末梢神経に電気的な刺激を与えて、その時の筋電図を検出することで、筋弛緩の程度を把握する機器です。

筋弛緩モジュール HN-100

医療機器認証番号:303ADBZX00112000

 **FUKUDA**

 **SENZIME**


2024 US Commercial expansion

- **Expansion of the US-based sales team** with additional Area Territory Managers.
- **Recruitment of Michael Noble** as Vice President Global Marketing and joins the Executive Leadership Team.
- **Relocation of US headquarters from Boston to St. Louis**, to enable more rapid, cost-effective, and sustainable shipments to hospitals across the US.
- **Cost-neutral expansion.**




Product market mix and market pricing affects Gross Margin

Development of COGS (MSEK) and Gross Margin rolling 12-months (%)



Sales growth with operating expense control

Operating expenses including currency related effects (kSEK)



Strong investor base secures Senzime's long-term plans




Handelsbanken Fonder



— As of March 30, 2024 —

| Ten largest shareholders | Number of shares | Capital (%) |
|---|--------------------|--------------|
| Crafoord family and the Crafoord Foundation | 20,222,151 | 16,9 |
| Segulah Venture AB, Segulah AB, Segulah Medical Acceleration AB | 12,803,271 | 10,7 |
| Handelsbanken Fonder | 8,615,496 | 7,2 |
| Fjärde AP-fonden | 7,571,578 | 6,3 |
| Fredrik Rapp | 6,803,946 | 5,7 |
| IBKR Financial Services | 5,346,320 | 4,5 |
| TIN Ny teknik | 4,863,157 | 4,1 |
| Pershing LLC. | 4,861,863 | 4,1 |
| Swedbank Robur Microcap | 4,345,236 | 3,6 |
| Carnegie Småbolagsfond | 3,905,461 | 3,3 |
| Bank of New York | 3,537,692 | 3,0 |
| Others | 36,829,352 | 30,8 |
| Total number of shares | 119,705,523 | 100,0 |

Strong start of Q2 with more important commercial wins



From Kids to Robots:

Senzime secures multiple top-rated US hospital deals



Public tender winner:

Senzime Wins Another Major US Veterans Affairs contract in Public Tender process



GPO Contract:


Senzime signs its first GPO contract with major US Hospital System as sole source supplier



Jan-April 2024:

Strong sales traction as we enter the second quarter with triple digit growth.

The Senzime 300 equation



The diagram illustrates the 'Senzime 300 equation' as a horizontal sequence of four dark blue circles. The first circle contains the number '300', followed by a red 'X' operator. The second circle contains the number '30', followed by another red 'X' operator. The third circle contains the number '4', followed by a red '=' operator. The final circle contains the number '300'. Below each circle is a descriptive label in dark blue text.

| 300 | X | 30 | X | 4 | = | 300 |
|-------------------|---|---------------------------------------|---|---|---|---------------------------------|
| Hospital accounts | | Average # of TetraGraphs per hospital | | Average use of TetraSens per monitor and week | | Million SEK in consumable sales |

Goal is that Senzime shall reach sales of around 300 MSEK in 2025, reach a market share of at least 10% in its addressed market segments and reach a long-term EBITDA margin exceeding 40%.

“We’re the fastest growing medical device company on Nasdaq Stockholm”



World-class technology
driving patient safety by
perioperative, precision-based
monitoring in over 300 hospitals

Brilliant team,
commercial operations in
over 30 markets and strong
investor backing

New clinical guidelines
in US and EU in support of
Senzime’s products, driving
a major paradigm shift

Our new vision:

**A world where
every clinician is
empowered,
and every
patient assured.**

**Revolutionizing
perioperative care.
Smart and simple.**

Our mission is to safeguard every patient's journey, from anesthesia to recovery.

We do this by developing user-friendly precision-based monitoring solutions, based on decades of science, that drive a perioperative digital transformation.

Our commitment propels healthcare providers to reach a new level of patient care, where every clinician is empowered, every patient assured, and the highest standards of care are not just met – they're invented.